ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,127.79
      1.26%
      US Tech 100
      17,446.00
      2.17%
      Dow Jones
      38,675.68
      1.18%
      Brent Oil
      82.765
      0.00%
      Bitcoin
      63,993.67
      0.16%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Soligenix Inc (SNGX)

      7. Soligenix Inc (SNGX) News

      SNGX

      Soligenix (SNGX)

      Soligenix Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:SNGX
      DateTimeSourceHeadlineSymbolCompany
      04/25/20247:30AMPR Newswire (US)Soligenix Extends Patent Protection for its Filovirus Vaccine Platform to the United Kingdom and South AfricaNASDAQ:SNGXSoligenix Inc
      04/18/20248:30AMPR Newswire (US)Soligenix Announces Pricing of $4.75 Million Public OfferingNASDAQ:SNGXSoligenix Inc
      04/15/20247:30AMPR Newswire (US)FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus InfectionNASDAQ:SNGXSoligenix Inc
      04/11/20247:30AMPR Newswire (US)FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Sudan Ebolavirus InfectionNASDAQ:SNGXSoligenix Inc
      04/03/20247:30AMPR Newswire (US)Soligenix Announces Agreement on the Design of a Second Confirmatory Placebo-Controlled Trial for HyBryte™ With the European Medicines AgencyNASDAQ:SNGXSoligenix Inc
      03/15/20247:30AMPR Newswire (US)Soligenix Announces Recent Accomplishments and Year End 2023 Financial ResultsNASDAQ:SNGXSoligenix Inc
      02/08/20247:30AMPR Newswire (US)Soligenix Announces Formation of Behçet's Disease Medical Advisory BoardNASDAQ:SNGXSoligenix Inc
      01/25/20247:30AMPR Newswire (US)Soligenix to Present at The Microcap ConferenceNASDAQ:SNGXSoligenix Inc
      01/08/20247:30AMPR Newswire (US)FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's DiseaseNASDAQ:SNGXSoligenix Inc
      01/04/20247:30AMPR Newswire (US)Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate PsoriasisNASDAQ:SNGXSoligenix Inc
      01/02/20247:30AMPR Newswire (US)Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg VirusesNASDAQ:SNGXSoligenix Inc
      12/22/20234:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNGXSoligenix Inc
      12/18/202312:15AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:SNGXSoligenix Inc
      12/15/20234:10PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNGXSoligenix Inc
      12/15/20234:10PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNGXSoligenix Inc
      12/15/20234:10PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNGXSoligenix Inc
      12/15/20234:10PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNGXSoligenix Inc
      12/15/20234:03PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNGXSoligenix Inc
      12/08/20235:12PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNGXSoligenix Inc
      12/08/20235:11PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNGXSoligenix Inc
      12/08/20235:10PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNGXSoligenix Inc
      12/08/20235:10PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNGXSoligenix Inc
      12/08/20234:05PMEdgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]NASDAQ:SNGXSoligenix Inc
      12/01/20237:30AMPR Newswire (US)"HyBryte™ Use in Early-Stage Cutaneous T-Cell Lymphoma" Published in Frontiers in Drug DiscoveryNASDAQ:SNGXSoligenix Inc
      11/30/20237:30AMPR Newswire (US)Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in the Treatment of Aphthous Ulcers in Behçet's DiseaseNASDAQ:SNGXSoligenix Inc
      11/17/20234:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNGXSoligenix Inc
      11/17/20234:00PMPR Newswire (US)Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual MeetingNASDAQ:SNGXSoligenix Inc
      11/13/20234:00PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SNGXSoligenix Inc
      11/13/20237:30AMPR Newswire (US)Soligenix Announces Recent Accomplishments And Third Quarter 2023 Financial ResultsNASDAQ:SNGXSoligenix Inc
      10/20/20234:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNGXSoligenix Inc
       Showing the most relevant articles for your search:NASDAQ:SNGX